Clinical Trial News and Research

RSS

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC

Inspire Pharmaceuticals, Inc. announced today Inspire scientists and collaborators will present data from the denufosol tetrasodium cystic fibrosis (CF) program in a poster presentation at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) October 15 - 17, 2009 in Minneapolis, MN.

15 Oct 2009

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

Sangretech Biomedical LLC, a developer of dendritic cell therapies for cancer and infectious diseases, today announced it has executed an amended and restated license agreement with Bostwick Laboratories, Inc. providing Bostwick Scientific, the research division of Bostwick Laboratories, with exclusive rights to Sangretech’s dendritic cell technology in certain territories.

15 Oct 2009

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Protalix BioTherapeutics, Inc., announced today positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive patients diagnosed with Gaucher disease.

15 Oct 2009

Medifacts International bags $2.7 million contract with a top ten pharmaceutical company

MEDIFACTS INTERNATIONAL, INC., one of the largest global providers of noninvasive cardiac diagnostic services, today announced the award of a $2.7 million contract with a top ten pharmaceutical company to provide comprehensive cardiac safety and efficacy services for a large late stage clinical trial.

15 Oct 2009

pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit

pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that the last patient in the Phase III clinical trial being conducted by its collaborative partner, Alimera Sciences, for a new treatment for diabetic macular edema (DME) has completed the two-year follow up visit.

15 Oct 2009

Phase Forward and Merck project wins the Society for Clinical Data Management Data Driven Innovation Award

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced that a joint project with customer Merck & Co. has won the 2009 Society for Clinical Data Management (SCDM) Data Driven Innovation Award competition. This annual honor recognizes the year’s best advancement in clinical data management technology or service.

15 Oct 2009

Endoscope: Less invasive alternative to laparoscopic techniques or conventional surgery

Mayo Clinic surgical researchers are reporting a 93 percent success rate in recent animal tests of endoscopic repair of perforated ulcers. The goal is to advance the use of an endoscope -- which allows access to organs through natural openings, such as the mouth -- for a less invasive alternative to laparoscopic techniques (surgery performed through a small incision) or conventional surgery.

15 Oct 2009

Health Sciences South Carolina, Recombinant Data and Sun Microsystems to collaborate on an Integrated Platform for Research

Health Sciences South Carolina (HSSC), today announced that it has selected Recombinant Data Corp. and Sun Microsystems, Inc. to collaborate on the Health Sciences South Carolina Integrated Platform for Research (HS-SCIPR), an unprecedented statewide initiative for translational research and quality improvement.

15 Oct 2009

National Institutes of Health grants $12 million to WCDRC for obesity research

The Miriam Hospital's Weight Control and Diabetes Research Center (WCDRC) recently received six research grants from the National Institutes of Health - totaling more than $12 million in funding - that will support the work of researchers focused on the prevention and treatment of obesity.

15 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that it has enrolled the first patients in Phase III clinical trials for its autism treatment, CM-AT. The first clinical trial patients have been enrolled at Lake Mary Pediatrics in Orange City, Florida, one of 12 clinical trial sites with a total 170 children across the country.

15 Oct 2009

Interim data from Sanofi Pasteur's Influenza A 2009 Monovalent Vaccine clinical trials in infants and children

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today an interim analysis of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in infants and children 6 months through 9 years of age. The data indicate the vaccine is immunogenic and that one dose may protect many children.

15 Oct 2009

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Jazz Pharmaceuticals, Inc. announced that data from the company's first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented during the American College of Rheumatology 2009 Annual Meeting (ACR) in Philadelphia, Pennsylvania and also in November during the US Psychiatric and Mental Health Congress (US Psych Congress) in Las Vegas, Nevada.

15 Oct 2009

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Cardium Therapeutics today reported positive data from its Matrix Phase 2b clinical trial of Excellarate(TM) for the potential treatment of patients with chronic non-healing diabetic foot ulcers based on the Company's Gene Activated Matrix (GAM) technology platform.

15 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Progenics Pharmaceuticals, Inc. today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth under which Progenics is regaining all worldwide rights to the RELISTOR® franchise from Wyeth Pharmaceuticals, which Progenics had previously licensed to Wyeth Pharmaceuticals.

14 Oct 2009

Women with breast cancer can improve their mental health through Transcendental Meditation technique

Women with breast cancer reduced stress and improved their mental health and emotional well being through the Transcendental Meditation technique, according to a new study published in the current issue of the peer-reviewed Integrative Cancer Therapies (Vol. 8, No. 3: September 2009).

14 Oct 2009

Clinical Trial News and Research

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Medifacts International bags $2.7 million contract with a top ten pharmaceutical company

pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit

Phase Forward and Merck project wins the Society for Clinical Data Management Data Driven Innovation Award

Endoscope: Less invasive alternative to laparoscopic techniques or conventional surgery

Health Sciences South Carolina, Recombinant Data and Sun Microsystems to collaborate on an Integrated Platform for Research

National Institutes of Health grants $12 million to WCDRC for obesity research

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Interim data from Sanofi Pasteur's Influenza A 2009 Monovalent Vaccine clinical trials in infants and children

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

EMEA grants ArQule's ARQ 197 orphan drug designation

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Women with breast cancer can improve their mental health through Transcendental Meditation technique

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News